Penn Vet | Clinical Trial Detail - Cathepsin-activated near-infrared (NIR) imaging for intraoperative detection of insulinomas
New Bolton Center Kennett Square, PA
Emergencies & Appointments:
Ryan Hospital Philadelphia, PA

Cathepsin-activated near-infrared (NIR) imaging for intraoperative detection of insulinomas

Aug 1, 2022

Insulinoma is the most common cancer of the pancreas in dogs. Insulinomas have a high rate of metastasis (spread) to other areas of the body including the adjacent lymph nodes, liver, and elsewhere. The treatment of choice is surgical removal of the primary tumor and sites of metastasis, when possible.

The aim of this study is to improve detection of surgical margins and metastatic lymph nodes at the time of surgery to remove the tumor. This is vital in both veterinary and human surgical oncology to minimize the chance of local recurrence. We are using a new near-infrared imaging agent injected intravenously and a novel imaging system to identify the tumor and its margins during surgery. This imaging adds no more than 15 minutes to a surgical procedure.


  • Dogs with suspected insulinoma and eligible for surgical excision
  • Not currently undergoing treatment for cancer
  • Not currently receiving alternative/holistic medications or supplements
  • No other significant health concerns that are an immediate threat to life outside of trial
  • Ability to attend visits at Penn Vet in Philadelphia


  • $2000 paid towards the cost of surgery

Please contact the VCIC at 215-573-0302 or for more information about this study.